How would you approach giving concurrent chemoradiation for Stage IIIB lung adenocarcinoma in the setting of concurrent Int-2 myelofibrosis which has been stable without cytopenias on ruxolitinib?
Would you modify the radiation dose or field in this setting?
Would you pre-emptively dose reduce chemotherapy, or modify the dosing of ruxolitinib?